CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
cetuximab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02324608
NCT02324608N/ACompleted
CompareCT.gov

A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)

Rutgers, The State University of New Jersey·interventional·Posted Dec 24, 2014·Updated Dec 20, 2023

In Brief

A clinical study evaluating cetuximab and laboratory biomarker analysis for Recurrent Skin Cancer and Squamous Cell Carcinoma of the Skin. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways be targeting certain cells. Giving cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Rutgers Cancer Institute of New Jersey

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 24, 2014
Enrollment StartJan 30, 2015
Primary CompletionDec 9, 2020
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.5 years ago

Interventions

cetuximabbiological

Given IV

laboratory biomarker analysisother

Correlative studies